Optic papillitis

disease
On this page

Also known as Choked discChoked discsChoked diskChoked disksdecreased intraocular pressure associated papilledemadecreased intraocular pressure-associated papilledemadisk, Chokeddisks, Chokededema of the optic diskedema, optic discedema, optic diskedema, optic papillaedema, retinalEdemas, optic discEdemas, optic diskEdemas, retinalincreased intracranial pressure associated papilledemaincreased intracranial pressure-associated papilledemainflammation of optic discinflammation of optic disk

Summary

Optic papillitis (MONDO:0006879) is a disease and 15 clinical trials. Top therapeutic interventions include anakinra and semaglutide. A subtype of retinitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 15

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameoptic papillitis
Mondo IDMONDO:0006879
EFOEFO:1001074
MeSHD010211
DOIDDOID:10175
ICD-10-CMH46.0
SNOMED CT423341008, 73221001
UMLSC0030353
MedGen10565
GARD0024496
MedDRA10030948
Is cancer (heuristic)no

Also known as: Choked disc · Choked discs · Choked disk · Choked disks · decreased intraocular pressure associated papilledema · decreased intraocular pressure-associated papilledema · disk, Choked · disks, Choked · edema of the optic disk · edema, optic disc · edema, optic disk · edema, optic papilla · edema, retinal · Edemas, optic disc · Edemas, optic disk · Edemas, retinal · increased intracranial pressure associated papilledema · increased intracranial pressure-associated papilledema · inflammation of optic disc · inflammation of optic disk (+20 more)

Disease family

This is a subtype of retinitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorderretinal disorderretinitisoptic papillitis

Related subtypes (4): cytomegalovirus retinitis, histoplasmosis retinitis, acute retinal necrosis syndrome, retinal vasculitis

Subtypes (1): neuroretinitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Dexamethasone.

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified9
PHASE42
PHASE2/PHASE31
PHASE1/PHASE21
PHASE11
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04501367PHASE4UNKNOWNAssessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.
NCT06027567PHASE4COMPLETEDThe Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
NCT01273727PHASE2/PHASE3COMPLETEDOzurdex for Macular Edema Post Membrane Peeling
NCT00069329PHASE1/PHASE2TERMINATEDAnakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
NCT03373292PHASE1UNKNOWNEndovascular Stenting Treatment for Patients With Internal Jugular Vein Stenosis
NCT04690608EARLY_PHASE1UNKNOWNSuprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema, CRVO, Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema Following Pars Plana Vitrectomy
NCT06286696Not specifiedNOT_YET_RECRUITINGOptic Nerve Sheath Diameter in Hypertensive Emergency
NCT01847638Not specifiedCOMPLETEDProlensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
NCT02410148Not specifiedUNKNOWNaICP in Glaucoma and Papilledema
NCT02992262Not specifiedUNKNOWNOcular Point of Care Ultrasound (POCUS) to Detect Optic Disc Swelling in Comparison to Ophthalmologic Examination
NCT03178760Not specifiedCOMPLETEDDetermination of Normal Measures of Optic Nerve Sheath Diameter in Children
NCT03273179Not specifiedUNKNOWNCerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment Scales
NCT03753893Not specifiedCOMPLETEDOcular Manifestations in Rheumatic Diseases
NCT05130385Not specifiedUNKNOWNHigh Resolution Optical Coherence Tomography
NCT06390579Not specifiedCOMPLETEDBuilding Research With Artificial Intelligence in Neuro-Ophthalmology

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
ANAKINRA41
SEMAGLUTIDE41
CHEMBL1572001
CHEMBL455678801
CHEMBL475233101
CHEMBL614786401
CHEMBL522061801